DMAA (1,3-dimethylamylamine) is an aliphatic amine added to some dietary supplement (DS) products. We are responding to the Research Letter by Cohen,1 in which he discussed natural occurrence of DMAA, as well as labeling it a potent “amphetamine derivative” linked in case reports and the news media to adverse cardiovascular toxic effects. We would like to offer the following points in the interest of moving forward the discussion of the health effects of DMAA within the context of sound toxicological and risk assessment principles.